24 May 2022 : Review article
A Systematic Review of the Literature on Chronic Kidney Disease Following Liver Transplantation
Hitomi Miyata1ADE*, Yoshiaki Morita2ADE, Anil Kumar3DEDOI: 10.12659/AOT.935170
Ann Transplant 2022; 27:e935170
Supplementary Table 1 Immunosuppressive treatment dose and trough levels during follow-up for the included studies.
Author, year [ref] | Study arm | n | Timepoint | Mean±SD TAC dose, mg | Mean±SD TAC trough level, ng/mL | Mean±SD MMF dose, mg/day | Mean±SD everolimus trough level, ng/mL |
---|---|---|---|---|---|---|---|
Lin KH et al, 2017 []18 | 18 | Baseline to 12 months | – | Mean ranged from >3– | – | – | |
23 | Baseline to 12 months | – | Mean ranged from >3.0– | – | – | ||
Chen WY et al, 2017 []23 | 14 | 1 month | – | 0.93 ng/mL/mg | – | – | |
3 months | – | 0.92 ng/mL/mg | – | – | |||
5 months | – | 0.63 ng/mL/mg | – | – | |||
7 months | – | 0.78 ng/mL/mg | – | – | |||
9 months | – | 0.73 ng/mL/mg | – | – | |||
11 months | – | 0.57 ng/mL/mg | – | – | |||
13 months | – | 0.66 ng/mL/mg | – | – | |||
15 months | – | 1.00 ng/mL/mg | – | – | |||
17 months | – | 1.10 ng/mL/mg | – | – | |||
28 | 1 month | – | 0.88 ng/mL/mg | – | – | ||
3 months | – | 0.88 ng/mL/mg | – | – | |||
5 months | – | 1.05 ng/mL/mg | – | – | |||
7 months | – | 1.05 ng/mL/mg | – | – | |||
9 months | – | 1.28 ng/mL/mg | – | – | |||
11 months | – | 1.12 ng/mL/mg | – | – | |||
13 months | – | 0.96 ng/mL/mg | – | – | |||
15 months | – | 1.58 ng/mL/mg | – | – | |||
17 months | – | 1.42 ng/mL/mg | – | – | |||
Lladó L et al, 2019 []26 | 69 | Transplantation | – | – | 1.0±0.5 g/12 hours | – | |
1 day | – | – | 1.0 g/12 hours | – | |||
2 days | 6.6 | 7.3 | 1.1 g/12 hours | – | |||
7 days | 10.9 | 9.5±6.3 | 1.1 g/12 hours | – | |||
10 days | 10.3 | 9.4±5.4 | 1.1 g/12 hours | – | |||
1 month | 8.4 | 8.0±3.1 | 1.2 g/12 hours | – | |||
3 months | 7.8 | 7.8±3.7 | 1.3 g/12 hours | – | |||
6 months | 6.1 | 8.0±4.1 | 1.3 g/12 hours | – | |||
12 months | 5.1 | 7.2±3.1 | 1.3±0.4 g/12 hours | – | |||
Hong S et al, 2017 []27 | 48 | 0 weeks (treatment initiation) | 1.2±0.6 | – | 708.3±249.1 | – | |
1 week | 3.1±1.0 | – | 937.5±167.1 | – | |||
2 weeks | 4.9±1.8 | – | 988.6±75.4 | – | |||
4 weeks | 4.9±1.9 | – | 976.7±152.5 | – | |||
6 weeks | 5.0±2.0 | – | 976.2±107.8 | – | |||
8 weeks | 5.0±1.8 | – | 1000.0±0.0 | – | |||
12 weeks | 4.8±1.9 | – | 1000.0±0.0 | – | |||
16 weeks | 4.4±1.8 | – | 1000.0±0.0 | – | |||
20 weeks | 4.1±1.6 | – | 1000.0±0.0 | – | |||
24 weeks | 4.0±1.7 | – | 1000.0±0.0 | – | |||
Jochmans I et al, 2017 []28 | 21 | 1 day (post transplantation) | – | Median (IQR)1 (1–2) | – | – | |
2 days | – | 3 (1–4) | – | – | |||
3 days | – | 5 (2–8) | – | – | |||
4 days | – | 6 (5–8) | – | – | |||
5 days | – | 6 (5–8) | – | – | |||
59 | 1 day (post transplantation) | – | Median (IQR)1 (1–1) | – | – | ||
2 days | – | 2 (1–4) | – | – | |||
3 days | – | 5 (2–8) | – | – | |||
4 days | – | 6 (3–9) | – | – | |||
5 days | – | 6 (5–9) | – | – | |||
Dopazo C et al, 2018 []29 | 20 | 7 days | – | Median (range)3 (1–8) | – | – | |
Sharma P et al, 2019 []7 | 93 | 1 month | – | Median (IQR)8.2 (7.0–9.6) | – | – | |
6 months | – | 6.7 (5.6–8.6) | – | – | |||
12 months | – | 6.7 (5.3–7.8) | – | – | |||
Last follow-up | – | 5.6 (4.2–7.7) | – | – | |||
Lim Y-T et al, 2020 []19 | 78 | Discharge | Median9 | – | – | – | |
3 days to 15 days post transplantation | – | WITHOUT basiliximab induction: median ranged from >2.5–1– | – | – | |||
30 days to 180 days post transplantation | – | WITHOUT basiliximab induction: median ranged from >6–6– | – | – | |||
Saliba F et al, 2017 []22 | 93 | Between transplantation and randomization | – | – | 1312±312 (EC-MPS) | – | |
Randomization | – | 8.8±3.1 | – | – | |||
Transplantation to 16 weeks | – | – | – | ||||
16 weeks | – | – | – | 7.2±3.5 | |||
24 weeks | – | – | 1131±394 (EC-MPS) | 7.7±3.5 | |||
95 | Between transplantation and randomization | – | – | 1349±252 (EC-MPS) | – | ||
Randomization | – | 8.7±4.0 | – | – | |||
24 weeks | – | 7.8±2.7 | 1125±400 (EC-MPS) | – | |||
Yoon K et al, 2018 []21 | 11 | Time of first GFR measurement | – | 5.0±1.85 | – | – | |
30 | Time of first GFR measurement | – | 4.7±2.3 | – | – | ||
10 | Time of first GFR measurement | – | 5.0±2.2 | – | – | ||
* ATG first dose mean±SD, 74±10 mg (n=20); second dose: 79±7 mg (n=13); third dose: 78±16 mg (n=4); median (range) dose: 1.96 (0.65–4.16) mg/kg; median (range) total dose: 160 (50–300) mg. ** Steroids were given to most patients (everolimus group 97.8% of patients, tacrolimus group 96.8%) at transplantation. At week 12, 78.0% and 84.9% of patients in the everolimus and tacrolimus groups, respectively, were receiving steroids (median daily dose 0.1 mg/kg in both groups [8.0 and 6.0 mg/day, respectively]); at week 24, 58.4% and 55.7% of patients, respectively, were receiving steroids (median daily dose 0.1 mg/kg [5.0 mg/day] in both groups). AKI – acute kidney injury; ATG – anti-human T-lymphocyte globulin; EC-MPS – enteric-coated mycophenolate sodium; GFR – glomerular filtration rate; IL-2 – interleukin 2; IQR – interquartile range; MMF – mycophenolate mofetil; OLT – orthotopic liver transplantation; QD – once daily; SD – standard deviation; TAC – tacrolimus. |